Olumiant is a prescription medication approved by the Food and Drug Administration (FDA) to treat moderate-to-severe rheumatoid arthritis in adults who have not responded adequately to one or more medications in the tumor necrosis factor (TNF) antagonist class. Olumiant is also known by its drug name, Baricitinib.
Olumiant is a targeted disease-modifying antirheumatic drug (DMARD). Olumiant is also a Janus kinase (JAK) inhibitor. Olumiant is believed to work by disrupting chemical signals involved in inflammation.
How do I take it?
Olumiant is taken orally once a day.
Olumiant comes in the form of a tablet.
The FDA-approved label for Olumiant lists common side effects including upper respiratory tract infections, nausea, cold sores, and shingles.
Rare but serious side effects listed for Olumiant can include life-threatening blood clots, perforation of the stomach or intestines, increased risk of severe infections, and an increased risk of developing certain types of cancer.
For more information, visit:
Olumiant – Lilly USA